Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Medtronic PLC is a medical devices business based in the US. Medtronic shares (MDT) are listed on the NYSE and all prices are listed in US Dollars. Medtronic employs 95,000 staff and has a trailing 12-month revenue of around $31.1 billion.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $82.27 |
|---|---|
| 52-week range | $81.62 - $126.49 |
| 50-day moving average | $90.80 |
| 200-day moving average | $99.86 |
| Wall St. target price | $108.49 |
| PE ratio | 21.3592 |
| Dividend yield | $2.57 (3.29%) |
| Earnings per share (TTM) | $3.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $82.27 from 2022-09-29
| 1 week (2022-09-23) | -0.47% |
|---|---|
| 1 month (2022-09-01) | -7.07% |
| 3 months (2022-07-01) | -9.97% |
| 6 months (2022-04-01) | -26.88% |
| 1 year (2021-10-01) | -35.38% |
|---|---|
| 2 years (2020-10-01) | -19.58% |
| 3 years (2019-10-01) | 108.22 |
| 5 years (2017-09-29) | 5.79% |
Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Medtronic shares trade at around 21x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4839. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.8 billion.
The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $31.1 billion |
|---|---|
| Operating margin TTM | 19.5% |
| Gross profit TTM | $21.7 billion |
| Return on assets TTM | 4.17% |
| Return on equity TTM | 10% |
| Profit margin | 16.75% |
| Book value | $39.63 |
| Market capitalisation | $109.9 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 26.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 12/31/2018) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.07/100
Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.28/100
Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9/100
Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.
Medtronic PLC was last rated for ESG on: 2019-01-01.
| Total ESG score | 26.86 |
|---|---|
| Total ESG percentile | 40.62 |
| Environmental score | 4.07 |
| Environmental score percentile | 5 |
| Social score | 15.28 |
| Social score percentile | 5 |
| Governance score | 9 |
| Governance score percentile | 5 |
| Level of controversy | 3 |
Dividend payout ratio: 49.06% of net profits
Recently Medtronic has paid out, on average, around 49.06% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.29% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 3.29% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.57 per share.
While Medtronic's payout ratio might seem fairly standard, it's worth remembering that Medtronic may be investing much of the rest of its net profits in future growth.
Medtronic's most recent dividend payout was on 13 October 2022. The latest dividend was paid out to all shareholders who bought their shares by 21 September 2022 (the "ex-dividend date").
Medtronic's shares were split on a 2:1 basis on 26 September 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.
Over the last 12 months, Medtronic's shares have ranged in value from as little as $81.62 up to $126.4895. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.7627. This would suggest that Medtronic's shares are less volatile than average (for this exchange).
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.